This course has expired. View available courses.
Endocrinology
Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies – QI&CPD – Category 2
The availability of new insulin therapies has led to new opportunities in the management of type 2 diabetes (T2D), with insulin analogues and combinations demonstrating evidence-based improvements in hypoglycaemia, weight change, and cardiovascular risk factors/outcomes. This module examines two newer insulin therapies: the first is premixed basal insulin plus rapid acting insulin (RAI combination), and […]
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
QI & CPD - Category 2
EXPIRY DATE
2020-06-29
The availability of new insulin therapies has led to new opportunities in the management of type 2 diabetes (T2D), with insulin analogues and combinations demonstrating evidence-based improvements in hypoglycaemia, weight change, and cardiovascular risk factors/outcomes. This module examines two newer insulin therapies: the first is premixed basal insulin plus rapid acting insulin (RAI combination), and the second is single-injection fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 (GLP-1) receptor agonist (Note that these are not yet available in Australia). As hypoglycaemia is a major obstacle for patients with T2D to achieve glycaemic targets, this module will focus on the effects of newer insulin therapies on hypoglycaemia.
Faculty
Associate Professor Michael d'Emden
MBBS, PhD, FRACP
Director of Endocrinology and Diabetes
Royal Brisbane Hospital
Queensland, Australia)
John Eric Barlow
MBBS, MRACGP
Clinical Supervisor, University of Notre Dame, NSW
Surgical Assistant Strathfield Private Hospital, NSW
Westmead Private Hospital, NSW